DOI QR코드

DOI QR Code

Fatty Acid Modulation of Atherosclerosis by Peroxisome Proliferator- Activated Receptors

  • Erickson, Kent L. (Department of Cell Biology and Human Anatomy, University of California, School of Medicine, Davis) ;
  • Hubbard, Neil E. (Department of Cell Biology and Human Anatomy, University of California, School of Medicine, Davis) ;
  • Meinecke, Lynette M. (Department of Cell Biology and Human Anatomy, University of California, School of Medicine, Davis)
  • Published : 2002.12.01

Abstract

While atherosclerosis is a major killer, there is now concern that mortality from the disease will increase due to the rising incidence of type II diabetes. Because diet can potentially influence both diseases, it is important to elucidate the role of diet in the progression of atherosclerosis. In addition, the mechanisms involved in dietary-related alterations of the disease need to be defined to guide public health recommendations to reduce athero-sclerosis incidence and limiting unwanted side effects. Since diet is thought to play a role in atherosclerosis even without added complications due to type II diabetes, reducing the incidence of that metabolic disease will not be enough. While evidence is increasing that high intake of carbohydrate can lead to type II diabetes and atherosclerosis, the preponderance of existing evidence indicates that intake of specific fats as a major dietary causal factor. It has recently been hypothesized that a dietary fat link to atherosclerosis may depend partly on the activity of a transcriptional regulator, the peroxisome proliferator activated receptors (PPAR). Thusfar, PPAR $\alpha$, $\beta$/$\delta$ and ${\gamma}$, have been shown to play a major role in metabolism, inflammation, and cancer. Furthermore, PPAR may regulate specific processes associated with atherosclerosis such as triglyceride and low density lipoprotein (LDL) metabolism; the reverse cholesterol transport pathway; lipid accumulation within plaques; the local inflammatory response and plaque stability. Synthetic ligands for PPAR have been developed; however, natural ligands include specific fatty acids and their metabolites. Though the role of PPAR in atherosclerosis has been reported with respect to synthetic ligands, additional studies need to be done with established and possible natural ligands. In this review, we will focus on the relation of dietary fat to PPAR alteration of atherosclerosis.

Keywords

References

  1. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. 1999. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19: 2094-2104 https://doi.org/10.1161/01.ATV.19.9.2094
  2. Carlos TM, Harlan JM. 1994. Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101
  3. Kagawa Y, Nishizawa M, Suzuki M, Miyatake T, Hamamoto T, Goto K, Motonaga E, Izumikawa H, Hirata H, Ebihara A. 1982. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol 28: 441-453 https://doi.org/10.3177/jnsv.28.441
  4. Kromhout D, Bosschieter EB, Coulander de Lezenne C. 1985. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 312: 1205-1209 https://doi.org/10.1056/NEJM198505093121901
  5. Prichard BN, Smith CC, Ling KL, Betteridge DJ. 1995. Fish oils and cardiovascular disease. Br Med J 310: 819-820 https://doi.org/10.1136/bmj.310.6983.819
  6. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. 1997. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336: 1046-1053 https://doi.org/10.1056/NEJM199704103361502
  7. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. 1998. Fish consumption and risk of sudden cardiac death. JAMA 279: 23- 28 https://doi.org/10.1001/jama.279.1.23
  8. Soei LK, Lamers JM, Sassen LM, van Tol A, Scheek LM, Dekkers DH, van Meegen JR, Verdou PD. 1995. Fish oil: a modulator of experimental atherosclerosis in animals. In N-3 Fatty Acids: Prevention and Treatment in Vascular Disease. Kristensen S, Endres S, De Caterina R, Schmidt EB, eds. Springer, London. p 77-84
  9. Harris WS. 1989. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 30: 785-807
  10. Sanders TA, Hinds A. 1992. The influence of a fish oil high in docosahexaenoic acid on plasma lipoprotein and vitamin E concentrations and haemostatic function in healthy male volunteers. Br J Nutr 68: 163-173 https://doi.org/10.1079/BJN19920074
  11. Wahle KW, Rotondo D. 1999. Fatty acids and endothelial cell function: regulation of adhesion molecule and redox enzyme expression. Curr Opin Clin Nutr Metab Care 2: 109-115 https://doi.org/10.1097/00075197-199903000-00003
  12. Massaro M, Carluccio MA, De Caterina R. 1999. Direct vascular antiatherogenic effects of oleic acid: a clue to the cardioprotective effects of the Mediterranean diet. Cardiologia 44: 507-513
  13. Yu Y, Correll PH, Vanden Heuvel JP. 2002. Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPARγ-dependent mechanism. Biochim Biophys Acta 1581: 89-99 https://doi.org/10.1016/S1388-1981(02)00126-9
  14. Desvergne B, Wahli W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688 https://doi.org/10.1210/er.20.5.649
  15. Chinetti G, Fruchart JC, Staels B. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505 https://doi.org/10.1007/s000110050622
  16. Spencer NF, Poynter ME, Im SY, Daynes RA. 1997. Constitutive activation of NF-$\kappa$B in an animal model of aging. Int Immunol 9: 1581-1588 https://doi.org/10.1093/intimm/9.10.1581
  17. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82 https://doi.org/10.1038/34178
  18. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. 1999. PPAR $\alpha$ activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131 https://doi.org/10.1161/01.CIR.99.24.3125
  19. Carluccio MA, Massaro M, Bonfrate C, Siculella L, Maffia M, Nicolardi G, Distante A, Storelli C, De Caterina R. 1999. Oleic acid inhibits endothelial activation: A direct vascular antiatherogenic mechanism of a nutritional component in the mediterranean diet. Arterioscler Thromb Vasc Biol 19: 220- 228 https://doi.org/10.1161/01.ATV.19.2.220
  20. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, Nagy L. 2000. Role for peroxisome proliferator-activated receptor $\alpha$ in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87: 516-521 https://doi.org/10.1161/01.RES.87.6.516
  21. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S. 2001. The ligands/activators for peroxisome proliferator-activated receptor $\alpha$ (PPAR $\alpha$) and PPAR $\gamma$ increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50: 3-11 https://doi.org/10.1053/meta.2001.19415
  22. Pasceri V, Wu HD, Willerson JT, Yeh ET. 2000. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101: 235-238 https://doi.org/10.1161/01.CIR.101.3.235
  23. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A. 2002. PPAR $\alpha$ and PPAR$\delta$ activators inhibit cytokine-induced nuclear translocation of NF-$\kappa$B and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435: 143- 151 https://doi.org/10.1016/S0014-2999(01)01589-8
  24. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W, Kreuzer J. 2002. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-$\kappa$B and activator protein-1. Arterioscler Thromb Vasc Biol 22: 914-920 https://doi.org/10.1161/01.ATV.0000019009.73586.7F
  25. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. 2001. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534 https://doi.org/10.1161/01.CIR.103.21.2531
  26. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. 2002. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22: 656-661 https://doi.org/10.1161/hq0402.105901
  27. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. 1999. PPARγactivation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551 https://doi.org/10.1161/01.ATV.19.3.546
  28. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. 2002. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162: 179-185 https://doi.org/10.1016/S0021-9150(01)00696-7
  29. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. 2000. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin- 1$\beta$, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$) in primary endothelial cells. Life Sci 67: 863-876 https://doi.org/10.1016/S0024-3205(00)00680-9
  30. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. 2000. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-γ- induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164: 6503-6508 https://doi.org/10.4049/jimmunol.164.12.6503
  31. Forman BM, Chen J, Evans RM. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors $\alpha$ and $\delta$. Proc Natl Acad Sci USA 94: 4312-4317 https://doi.org/10.1073/pnas.94.9.4312
  32. Desvergne B, A IJ, Devchand PR, Wahli W. 1998. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J Steroid Biochem Mol Biol 65: 65-74 https://doi.org/10.1016/S0960-0760(97)00182-9
  33. Moya-Camarena SY, Vanden Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA. 1999. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPAR $\alpha$. J Lipid Res 40: 1426-1433
  34. Murase T, Kondo H, Hase T, Tokimitsu I, Saito M. 2001. Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates. Biochim Biophys Acta 1530: 15-22 https://doi.org/10.1016/S1388-1981(00)00162-1
  35. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. 1999. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389 https://doi.org/10.1172/JCI7145
  36. De Caterina R, Liao JK, Libby P. 2000. Fatty acid modulation of endothelial activation. Am J Clin Nutr 71: 213S- 223S
  37. Johansen O, Seljeflot I, Hostmark AT, Arnesen H. 1999. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 19: 1681- 1686 https://doi.org/10.1161/01.ATV.19.7.1681
  38. Miles EA, Thies F, Wallace FA, Powell JR, Hurst TL, Newsholme EA, Calder PC. 2001. Influence of age and dietary fish oil on plasma soluble adhesion molecule concentrations. Clin Sci (Lond) 100: 91-100 https://doi.org/10.1042/CS20000198